Skip to main content

A new breakthrough proposes a link between epilepsy and bipolar disorder

A new breakthrough proposes a link between epilepsy and bipolar disorder

  • Date21 August 2018

Research at Royal Holloway, University of London, has suggested a link between patients with epilepsy and patients with bipolar disorder, through investigating a medicine used to treat both disorders.

Bipolar disorder image to accompany Valproic acid research

Bipolar image

Valproic acid has been used successfully for many years to treat people with a diagnosis of either epilepsy or bipolar disorder, but there has never been a clear understanding of how it works for these two different conditions.  Unfortunately, the drug also has severe side effects, increasing the chance of causing birth defects, if taken by pregnant women.

Professor Robin Williams, Head of the Centre for Biomedical Sciences in Royal Holloway’s School of Biological Sciences, and his students have carried out extensive research to discover how the drug works. Their work has been published in the journal Disease Models & Mechanisms.

Robin said: “To enable us to understand how the drug works in both conditions, we carried out tests using a simple amoeba as a research model. Using this model to replace animals in research, we were able to identify a single protein affected by valproic acid. This protein has previously been associated with both conditions, however, our research has been the first to suggest that it may be the key linking the treatment of both disorders”.

“Now that we understand how valproic acid works, we have been able to design potential new drugs that would be effective in treating both conditions, without causing birth defects.”

 “Successfully developing these new drugs would be potentially life changing for women who want to have children, but depend on valproic acid to manage their condition”.

The next step for Robin and his colleagues is to find a partner organisation who will support the development of these new compounds. Development of these new drugs could lead to safer and more effective treatments for patients with epilepsy and bipolar disorder.

The initial research has been funded by NC3Rs

The full title of the paper is “Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in Dictyostelium discoideum.”

DOI: DMM/2018/035600

In the UK, there are around 500,000 people who have epilepsy and around 2.4 million who have bipolar disorder.

Explore Royal Holloway

Get help paying for your studies at Royal Holloway through a range of scholarships and bursaries.

There are lots of exciting ways to get involved at Royal Holloway. Discover new interests and enjoy existing ones

Heading to university is exciting. Finding the right place to live will get you off to a good start

Whether you need support with your health or practical advice on budgeting or finding part-time work, we can help

Discover more about our 21 departments and schools

Find out why Royal Holloway is in the top 25% of UK universities for research rated ‘world-leading’ or ‘internationally excellent’

Royal Holloway is a research intensive university and our academics collaborate across disciplines to achieve excellence.

Discover world-class research at Royal Holloway

Discover more about who we are today, and our vision for the future

Royal Holloway began as two pioneering colleges for the education of women in the 19th century, and their spirit lives on today

We’ve played a role in thousands of careers, some of them particularly remarkable

Find about our decision-making processes and the people who lead and manage Royal Holloway today